Scinai Immunotherapeutics Ltd. is focused on developing innovative immunotherapy treatments for cancer, leveraging its proprietary platform to create novel therapeutic candidates. The company operates primarily in Israel and aims to differentiate itself through its unique approach to targeting immune responses in tumor microenvironments.
Business Overview
Scinai Immunotherapeutics generates revenue primarily through research grants and strategic collaborations with larger pharmaceutical firms seeking to leverage its immunotherapy platform. The company has potential for licensing agreements and milestone payments as it progresses through clinical trials.
Progress in clinical trials for lead immunotherapy candidates
Partnership announcements with larger biopharma companies
Regulatory approvals or updates from health authorities
Changes in competitive landscape within the immunotherapy sector
Risk Factors
Regulatory changes that could impact drug approval processes
Technological disruption from competing immunotherapy innovations
Emergence of new entrants in the immunotherapy space with superior technology
Potential for larger pharmaceutical companies to outpace Scinai in clinical development
High operational losses leading to cash burn
Dependence on external funding sources for R&D
Macro Sensitivity
low - The demand for biopharmaceuticals is relatively inelastic, as healthcare spending tends to be stable regardless of economic cycles.
Moderate - Higher interest rates could increase the cost of capital for R&D financing, impacting the company's ability to fund clinical trials.
minimal - The company has a low debt-to-equity ratio, indicating limited reliance on credit markets.
Profile
growth - Investors seeking high-risk, high-reward opportunities in the biotech sector.
high - The stock has experienced significant volatility, evidenced by an 80% decline over the past year.
Explore More
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
